tetano
Editor, Senior Moderator
BMC Cardiovasc Disord
. 2022 Mar 9;22(1):93.
doi: 10.1186/s12872-022-02534-8.
Cardiovascular disturbances in COVID-19: an updated review of the pathophysiology and clinical evidence of cardiovascular damage induced by SARS-CoV-2
Ismaheel O Lawal[SUP] 1 2 [/SUP], Mankgopo M Kgatle[SUP] 3 4 [/SUP], Kgomotso Mokoala[SUP] 3 4 [/SUP], Abubakar Farate[SUP] 5 [/SUP], Mike M Sathekge[SUP] 3 4 [/SUP]
Affiliations
Abstract
Severe acute respiratory coronavirus-2 (SARS-Co-2) is the causative agent of coronavirus disease-2019 (COVID-19). COVID-19 is a disease with highly variable phenotypes, being asymptomatic in most patients. In symptomatic patients, disease manifestation is variable, ranging from mild disease to severe and critical illness requiring treatment in the intensive care unit. The presence of underlying cardiovascular morbidities was identified early in the evolution of the disease to be a critical determinant of the severe disease phenotype. SARS-CoV-2, though a primarily respiratory virus, also causes severe damage to the cardiovascular system, contributing significantly to morbidity and mortality seen in COVID-19. Evidence on the impact of cardiovascular disorders in disease manifestation and outcome of treatment is rapidly emerging. The cardiovascular system expresses the angiotensin-converting enzyme-2, the receptor used by SARS-CoV-2 for binding, making it vulnerable to infection by the virus. Systemic perturbations including the so-called cytokine storm also impact on the normal functioning of the cardiovascular system. Imaging plays a prominent role not only in the detection of cardiovascular damage induced by SARS-CoV-2 infection but in the follow-up of patients' clinical progress while on treatment and in identifying long-term sequelae of the disease.
Keywords: COVID-19; Cardiovascular disorders; Myocarditis; Positron emission tomography; SARS-CoV-2; Takotsubo cardiomyopathy; Thromboembolism.
. 2022 Mar 9;22(1):93.
doi: 10.1186/s12872-022-02534-8.
Cardiovascular disturbances in COVID-19: an updated review of the pathophysiology and clinical evidence of cardiovascular damage induced by SARS-CoV-2
Ismaheel O Lawal[SUP] 1 2 [/SUP], Mankgopo M Kgatle[SUP] 3 4 [/SUP], Kgomotso Mokoala[SUP] 3 4 [/SUP], Abubakar Farate[SUP] 5 [/SUP], Mike M Sathekge[SUP] 3 4 [/SUP]
Affiliations
- PMID: 35264107
- DOI: 10.1186/s12872-022-02534-8
Abstract
Severe acute respiratory coronavirus-2 (SARS-Co-2) is the causative agent of coronavirus disease-2019 (COVID-19). COVID-19 is a disease with highly variable phenotypes, being asymptomatic in most patients. In symptomatic patients, disease manifestation is variable, ranging from mild disease to severe and critical illness requiring treatment in the intensive care unit. The presence of underlying cardiovascular morbidities was identified early in the evolution of the disease to be a critical determinant of the severe disease phenotype. SARS-CoV-2, though a primarily respiratory virus, also causes severe damage to the cardiovascular system, contributing significantly to morbidity and mortality seen in COVID-19. Evidence on the impact of cardiovascular disorders in disease manifestation and outcome of treatment is rapidly emerging. The cardiovascular system expresses the angiotensin-converting enzyme-2, the receptor used by SARS-CoV-2 for binding, making it vulnerable to infection by the virus. Systemic perturbations including the so-called cytokine storm also impact on the normal functioning of the cardiovascular system. Imaging plays a prominent role not only in the detection of cardiovascular damage induced by SARS-CoV-2 infection but in the follow-up of patients' clinical progress while on treatment and in identifying long-term sequelae of the disease.
Keywords: COVID-19; Cardiovascular disorders; Myocarditis; Positron emission tomography; SARS-CoV-2; Takotsubo cardiomyopathy; Thromboembolism.